   Program Organisers Abstracts Participants |
2005
Pamplona, Spain
| Bergès A (1), Laporte S (1), Girard P (5), Epinat M (2), Zufferey P (3), Alamartine E (4), Decousus H (1,2), Mismetti P (1,2) for the PROPHRE-75 study Group*. Do we need a perfect basic structural model before exploring the covariate model? Example with enoxaparin |
| K. Brendel(1), E. Comets(1), C.Laveille(2), C. Laffont(2), F. Mentré(1) Metrics based on objective function for external validation of a population pharmacokinetic model |
| L. Claret (1), E.H. Cox (1), L. McFadyen (2), A. Pidgen (2), P.J. Johnson (2), S. Haughie (2), M. Boolell (2), R. Bruno (1) Modelling and Simulation of the Telephone Sexual Activity Daily Diary (TSADD) Data of patients with female sexual arousal disorder (FSAD) treated with sildenafil (Viagra). |
| L. Bueno (1), C. Pitou (2), S. Glatt (2), D. de Alwis (2), I.F. Trocóniz (1) Mechanistic PK/PD modelling for signal transduction modulators. Application to TGF-beta RI antagonists. |
| K.C. Carlsson(1), M. Bergjord(1), E.R. Moberg(2) and N.O. Hoem(1) Bioavailability of gabapentin assessed by cumulative urine sampling compared with a model for the saturated absorption of gabapentin. |
| Josep María Cendrós(1), Iñaki F. Trocóniz(2), Concepción Peraire(1), and Rosendo Obach(1) Population pharmacodynamic modelling of lanreotide (Lan) autogel (ATG) in patients with acromegaly |
| Anne Chain, Lutz Harnisch, Oscar Della Pasqua Separating Signal from Noise: PK/PD modelling of QT-interval prolongation |
| S. Chantel(1), P.Y. Petit(2), P. Martin(1), D. Massignon(3), F. Saulnier(2), M. Benoist(2), S. Granger(2), P. Maire(4,5), R.W. Jelliffe(5), G. Aulagner(1) Population pharmacokinetics of enoxaparin used for thromboembolism prophylaxis after total hip replacement |
| S. Chantel(1), P. Martin(1), P.Y. Petit(2), D. Massignon(3), F. Saulnier(2), M. Benoist(2), S. Granger(2), P. Maire(4,5), R.W. Jelliffe(5), G. Aulagner(1) Pharmacokinetics modelling and anti-Xa level simulation of enoxaparin used for venous thromboembolism prophylaxis after orthopaedic surgery |
| Xuejun Chen, Suresh Mallikaarjun Modeling of circadian effect on lung function in patients with chronic obstructive pulmonary disease |
| Chenel M (1, 2), Ogungbenro K (1), Duval V (2), Laveille C (2), Jochemsen R (2), Aarons L (1) Optimal blood sampling time windows for parameter estimation using a population approach: design of a Phase II clinical trial |
| S. Y. A. Cheung, I. Gueorguieva and L. Aarons Structural identifiability analysis of some semi-physiologically based and whole body physiologically based (WBPBPK) pharmacokinetic models. |
| Colom H1, Farré MR2, Soy D3, Peraire C1, Cendros JM1, Pardo N.2,Torrent M.2, Domenech J1, Mangues MA2 Population pharmacokinetics of high-dose methotrexate in osteosarcoma pediatric patients. |
| Emmanuelle Comets (1), Céline Verstuyft (2) and France Mentré (1) Building a pharmacogenetic model to describe the pharmacokinetics of digoxin |
| Valerie Cosson (1), Roberto Gomeni (1) Modelling placebo response in depression using a mechanistic longitudinal model approach |
| Dinesh de Alwis1, Sophie Callies1, James Wright2, Leon Aarons3 and Micheal Burgess1 Resisting population PK, the story of P-gp inhibition and co-administered chemotherapy. |
| ME de Jonge(1), ADR Huitema(1), AC Tukker (2), SM van Dam(1), S Rodenhuis(2), JH Beijnen(1,2). Prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa and carboplatin in high-dose chemotherapy. |
| C. Tillmann (1), H.G. Schaefer (1), T. Lehr (2), A. Staab (1) Meloxicam for juvenile rheumatoid arthritis patients: Is dosing on a mg/kg body weight basis justified? |
| Aristides Dokoumetzidis and Leon Aarons Propagation of population PK and PD information using a Bayesian approach: dealing with non-exchangeability |
| Sarayut Janmahasatian[1], Stephen B Duffull[1,5], Susan Ash[2], Leigh C Ward[3], Nuala M Byrne[4], Bruce Green[1,5] A Semi-Mechanistic Model For Quantification Of Lean Body Weight |
| Adrian Dunne Introduction to Categorical Data Analysis |
| Vincent Duval & Christian Laveille Ivabradine and S18982 activities on heart rate: a population PK/PD analysis |
| D. Elsherbiny(1), S. Asimus(2), M. Ashton(2), U. S. H. Simonsson(1) Population pharmacokinetics of S-mephenytoin and its metabolites S-nirvanol and S-4-hydroxymephenytoin in CYP2C19 poor, intermediate and extensive metabolizers. |
| David Hermann (1), Wenping Wang (2), Christine Falcoz (3), Daniel Hartman (1), Jaap Mandema (4) Strategies to Improve Model-based Decision-making During Clinical Development |
| Jan Freijer, Inez de Greef - van der Sandt, Teun Post, Bart Ploeger. Robust fitting of pharmacokinetic models to Phase II/III clinical trial data |
| Lena E Friberg(1), Geoffrey K Isbister(2), L Peter Hackett(3) and Stephen B Duffull(1) Pharmacokinetic-Pharmacodynamic Modelling of QT-Prolongation following Deliberate Self-Poisonings with Citalopram |
| D, Santos Buelga1, MM Fernandez de Gatta1, EV. Herrera2, A Dominguez-Gil1,3, MJ García1 Vancomycin population pharmacokinetic analysis in patients with hematological malignancies |
| P.L. Gambús (1), M.J. Garrido (2), J. Fernández-Candil (1), R. Valero (1), I.F. Trocóniz (2) and N. Fábregas (1) Pharmacokinetics and Pharmacodynamics of Rocuronium bromide in patients undergoing brain surgery: Influence of chronic Phenytoin therapy |
| Germani M (1), Simeoni M (2), Rocchetti M (1), Van der Graaf PH (3), Salhi S (3), Milligan P (3), Poggesi I (1). Implementation of variability in a physiologically-based pharmacokinetic approach for simulating the first-in-animal study. |
| E. Gibiansky(1), L. Gibiansky(2) Population PK/PD model of GPI 15715 and GPI-derived propofol in sedation and comparison of PK/PD models for ordered categorical observations |
| B. Knebel (1), T. Bergsma (2), L. Gibiansky (1), J.T. Hane (1), M.R. Gastonguay (1) NMQual: A Tool to Automate Installation and Facilitate Qualification of NONMEM |
| Pascal Girard and France Mentré A comparison of estimation methods in nonlinear mixed effects models using a blind analysis |
| S. Glatt(1), C Pitou (1), J. Yingling (1), L. Bueno (2), D. de Alwis (1), I.F Troconiz (2) Preclinical Population PK/PD of TGF beta RI Kinase inhibitor for Cancer |
| González-Álvarez I, Fernández-Teruel C, Navarro-Fontestad MC, Ruiz-Garcia A., Bermejo M, Casabó VG. Pharmacokinetics and bioavailability of new ciprofloxacin derivative (CNV 97101) in rat: repercussion of precipitation in stomach. |
| Bruce Green (1,2) , Howard Lee (1), Nathan Lack (3), D Dale (3), G Calandra (3), Ron MacFarland (3), K Badel (3), W Liles (4), G Bridger (3), Carl Peck (1) Use of an indirect effect model to describe the mobilization of progenitor cells induced by AMD3100 |
| B. Gruwez (1), M. Tod (1,2), A. Dauphin (1) A mathematical model for paroxetine antidepressant effect time course and its interaction with pindolol |
| Ivelina Gueorguieva, Leon Aarons, Karin M. Jorga and Malcolm Rowland Population Optimal Design for Multivariate Response Pharmacokinetic Models |
| Anna-Karin Hamberg (1), Marja-Liisa Dahl (1), Gabriella Scordo (1), Roberto Padrini (2), Martina Barban (2) and E. Niclas Jonsson (3) Pharmacokinetic/Pharmacodynamic Modelling of the Anticoagulant Activity of Warfarin |
| A. Henningsson(1), A. Sparreboom(2,3), W. J. Loos(3), J. Verweij(3), M. Silvander(4,5) and M. O. Karlsson(1) Population Pharmacokinetic Model for Cremophor EL |
| D Hirt (1), S Urien (2), V Jullien (1), G Firtion (1), E Rey (1), G Pons (1), S Blanche (3), and JM Treluyer (1) Age-related effects on nelfinavir - M8 pharmacokinetics - A population study in 182 children |
| Nick Holford (1), Nick Fleischer (2) Topical Corticosteroid Bioequivalence – An Evaluation of the FDA Guidance |
| Nick Holford The Visual Predictive Check – Superiority to Standard Diagnostic (Rorschach) Plots |
| Nick Holford Simultaneous modelling of disease progression and time to event with NONMEM – likelihood ratio test criteria for random and informative dropout models and an evaluation of two methods affecting the quality of parameter estimates |
| Nick Holford PKPD Workshop 'An overview on how to use NONMEM for PKPD analyses' |
| Andrew Hooker (1), William S. Kerwin (2) and Paolo Vicini (3). Simultaneous population D-optimal designs for contrast enhanced MRI measurements of atherosclerotic plaque neovasculature. |
| Andrew Hooker (1), A. J. Ten Tije (2), M. A. Carducci (3), H. Gelderblom (4), F. W. Dawkins (5), W. P. McGuire (6), J. Verweij (2), Mats O. Karlsson (1) and S. D. Baker (3). Population pharmacokinetic modeling of total and unbound docetaxel plasma concentrations in cancer patients with poor liver function |
| José Pinheiro(1), Chyi-Hung Hsu(1), and Fei Chen(2) Analyzing Event History Data with nlme in S |
| P.M. Jauslin (1, 2), H.E. Silber (1), N. Frey (2), R. Gieschke (2), U.S.H. Simonsson (1), K. Jorga (2), M.O. Karlsson (1) A Disease Model Describing the Regulation of the Glucose-Insulin System in Diabetic Patients after IVGTT and OGTT |
| M. Joerger(1,2) A.D.R. Huitema(1) H.J.G.D. van den Bongard(3) O. van Tellingen(4) P. Baas(2) J.H. Schornagel(2) J.H.M.Schellens(2,5) J.H. Beijnen(1,2,5) Determinants of the pharmacokinetics of methotrexate and its metabolite 7-hydroxy-methotrexate following high-dose infusional methotrexate |
| Patrick Johnson (1), Byron Jones (1), Barbara Bogacka (2), Oleg Volkov (2) Optimising PK sampling under the constraint imposed in later phase clinical trials |
| H.M. Jones(1), M. Pantze(1), A. Rakhit(2), T. Lavé(1), K. Jorga(2), J-E Charoin(2) Prediction of drug-drug interactions and their associated variability in human populations: Application to erlotinib and its coadministration with ketoconazole and rifampicin |
| V. Jullien(1), J.M. Tréluyer(1), E. Rey(1), P. Jaffray(1), A. Krivine(1), L. Moachon(1), A Lillo-Le Louet(2), A. Lescoat(1), N. Dupin(1), D. Salmon(1), G. Pons(1), S. Urien(1). Population pharmacokinetics of tenofovir in HIV-infected patients taking highly active antiretroviral therapy. |
| K. Karlsson, A. Grahnén, M.O. Karlsson and E.N. Jonsson Randomized exposure-controlled trials; impact of randomization and analysis strategies – from a toxicity perspective |
| B Hamrén (1), H Ericsson (1), P Öhman (1), D Anzalone (1), Mats O. Karlsson (2) A pooled population pharmacokinetic analysis of tesaglitazar in patients with type 2 diabetes or with manifestations of insulin resistance |
| Bengt Hamrén (1), Hans Ericsson (1), Peter Öhman (1), Ingrid Gause Nilsson (1) and Mats O. Karlsson (2) Pharmacokinetic and pharmacodynamic modelling of the dual PPAR α/γ agonist tesaglitazar in patients with manifestations of insulin resistance |
| Trevor N. Johnson(1), Thomas Kerbusch(3), Peter A. Milligan(3), Barry Jones(4), Geoffrey T. Tucker(1,2) and Amin Rostami-Hodjegan(1,2) The Efficiency of Mixed Effect Modelling to Detect Metabolism-Based Drug-Drug Interactions (mDDI) |
| MC Kjellsson (1), PH Zingmark (1, 2), EN Jonsson (1), MO Karlsson (1) A Study Comparing the Performance of the Proportional Odds Model to that of the Differential Drug Effect Model for Cumulative Logits |
| Andreas Krause, Florilene Bouisset, Amy Racine Modeling Discontinuation of Treatment in Non-Ignorable Situations |
| Marc Lavielle (1) and France Mentré (2) Estimation of population pharmacokinetic parameters of saquinavir in HIV patients and covariate analysis with MONOLIX |
| T. Lehr (1), C. Tillmann (2), A. Staab (2), H.G. Schaefer (2), C. Kloft (1) Evaluation of an enterohepatic circulation model: predicting the influence of cholestyramine on the pharmacokinetics of meloxicam |
| T. Lehr (1), C. Tillmann (2), A. Staab (2), R. Krug-Schmid (2), D. Trommeshauser (2), H.G. Schaefer (2), C. Kloft (1) A new CNS active drug and its metabolite: a population pharmacokinetic analysis |
| T. Lehr (1), C. Tillmann (2), A. Staab (2), D. Trommeshauser (2), R. Binder (2), H.G. Schaefer (2), C. Kloft (1) Assessment of the potency of a metabolite relative to the parent compound using a population PK/PD model for the inhibition of a neurotransmitter re-uptake transporter in mice |
| Annabelle Lemenuel-Diot and Christian Laveille Use of Time-to-event analysis to qualify activity of Ivabradine durign exercise tolerance tests |
| M. Levi(1), C. Ng (2), J-M. Gries (1), B. Davies (1) Population Pharmacokinetics of Rituximab in RA (Rheumatoid Arthritis) Patients: Combining two phase II studies |
| C. Lia Liefaard (1), Yoshi Tagawa (1,2), Meindert Danhof (1,3), Rob A. Voskuyl (1,4) Population Pharmacokinetic/Pharmacodynamic Analysis of Different Subunit Selective GABAergic Ligands in an Animal Model of Epilepsy |
| K.-H. Liesenfeld (1), J. Stangier (1), C. Garnett (2), C. Tillmann (1), I. Troconiz (3), H. Lee (2), H.G. Schaefer (1) PK/PD-Modeling (PK/PD) and Clinical Trial Simulation (CTS) of Early Clinical Data of a New Oral Direct Thrombin Inhibitor (Dabigatran Etexilate) |
| Mick Looby and Amy Racine An approach to formal decision making in exploratory development |
| John Lukas1, Angeliki Andrioti2, Anastasios Zografidis2, Monica Rodriguez2, Erasmia Psimenou3 Pharmacokinetics- guided targeting of mycophenolate mofetil (MMF) in combination renal transplantation treatment confirms the need for dose reduction |
| Alan Maloney(1), Klaas Zuideveld(2), Karin Jorga(2), Cornelia Weber(2), Nicolas Frey(2), Per Olsson(1), Eric Snoeck(1) An Application of Modelling and Simulation to Type 2 Diabetes: Development of a general drug-disease model based on a meta analysis of over 40 studies investigating 5 PPAR drugs |
| Mathilde Marchand (1), David Critchley (2), Christa Nagy (2), and Eliane Fuseau (1) The effect of rufinamide concentration on the QT interval in healthy subjects treated during 18 days with multiple ascending doses: a population PKPD analysis. |
| France Mentré History and new developments in estimation methods in nonlinear mixed-effects models |
| R. Miller, D. Ouellet, P. Burger, B.W. Corrigan Exposure-Response Analysis Using Time to Event Data: An Example Using Sleep Onset. |
| José Moltó(1), Marta Valle(2), Asunción Blanco(3), Meritxell DelaVarga(3), Cristina Miranda(1), José Miranda(1), Joan Costa(4), Manuel José Barbanoj(2), Bonaventura Clotet(1,3). Population pharmacokinetics of lopinavir in HIV-infected adults receiving lopinavir/ritonavir |
| Nalda-Molina R. (1), Casabó V.G. (2), Bermejo M. (2) A simple physiological-pharmacokinetic model to simulate bioequivalence trials |
| Brunhild Schiltmeyer, Willi Cawello, Dirk Kropeit, Rolf Horstmann Population pharmacokinetics of the new antiepileptic drug lacosamide in healthy subjects with different age and gender |
| Elisabet Nielsen (1), Anders Viberg (1), Otto Cars (2) and Marie Sandström (1) A Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model for Antibiotics |
| Gianluca Nucci 1, Regan Fong 2, David J. Carpenter 2, Roberto Gomeni 1 Population pharmacokinetics of paroxetine in the pediatric population |
| Panhard X (1), Legrand M (1), Taburet AM (2), Diquet B (3), Goujard C (2), Mentré F (1) and the Cophar 1 – ANRS 102 study group High Inter-Patient Variability of Pharmacokinetics of Lamivudine (LMV), Stavudine (STV) and Zidovudine (ZDV) in HIV-Infected Patients treated with HAART (Cophar 1 – ANRS 102 Study). |
| Xavière Panhard and France Mentré Non-linear mixed-effects models for tests of interaction or of lack of interaction in cross-over and parallel pharmacokinetic studies: application to the test of interaction between protease inhibitors and nucleoside analogs in HIV patients |
| P Olsson Gislekog (1), P Jacqmin (1), JJ Perez Ruixo (2). Population Pharmacokinetics of rHuEpo in Healthy volunteers. |
| O. Pétricoul (1), V. Cosson (2), C. Crépin (1), E. Fuseau (1), D. Critchley (3) Understanding the variability in clinical response to rufinamide, a new antiepileptic drug: a pooled PKPD analysis |
| V. Piotrovsky Indirect-response model for the analysis of concentration-effect relationships in clinical trials where response variables are scores |
| T.M. Post(1), W. de Winter(1), J. DeJongh(1, 2), I. Moules(3), R. Urquhart(3), D. Eckland(3) and M. Danhof(1, 2) Treatment Efficacy of Combination-Therapy based on a Mechanistic Characterisation of Disease Processes in Type 2 Diabetes Mellitus over a two-year period |
| A. Quartino(1), M.O. Karlsson(1), A. Freijs(1), N. Jonsson(1), P. Nygren (3), J. Kristensen (2), E. Lindhagen (2) and R. Larsson (2) Population Based Pharmacodynamics for In Vitro Drug Sensitivity Assays: Prediction of Model Based Parameters of Drug Activity and Relationship to Clinical Outcome |
| Sylvie Retout, Emmanuelle Comets, Adeline Samson and France Mentré Designs in nonlinear mixed effects models: application to HIV viral load decrease with evaluation, optimization and determination of the power of the test of a treatment effect |
| Sylvie Retout, Jean-Eric Charoin, Karin Jorga Relevance of the use of population design evaluation and optimisation methods in the context of drug development projects in Roche |
| L.Reyderman (1), A. Shah(1), P.Statkevich(1) Designing Sparse-Sampling Schemes for Population PK Study of a Highly Variable Drug. |
| Jakob Ribbing, Joakim Nyberg and E. Niclas Jonsson The Lasso - A Novel Method for Predictive-Covariate Modelling of Population Pharmacokinetics/Pharmacodynamics |
| N. Rivas, D Santos Buelga, J. Santos Borbujo, MJ Otero, A. Domínguez-Gil1, MJ García Population pharmacokinetics of lamotrigine in epileptic patients with data proceeding of therapeutic drug monitoring |
| M. C. Rosario (1), P. Jacqmin (2), P. Dorr (3), M. Westby (3), E. van der Ryst (3) C. Hitchcock (3) & S. Felstead (3) Model-based drug development of a new anti-HIV drug |
| Adeline Samson (1), Xavière Panhard (1), Marc Lavielle (2) and France Mentré (1) Generalisation of the SAEM algorithm to nonlinear mixed effects model defined by differential equations : application to HIV viral dynamic models |
| Gijs Santen(1), Roberto Gomeni(2), Meindert Danhof(1) and Oscar Della Pasqua(1) Modelling of the Hamilton Depression Rating Scale in Unipolar Depression Trials |
| Edginton, A.E., S. Willmann, W. Schmitt Prediction of Clearance in Children Using a Combined Physiology-based and Enzyme Ontogeny Approach |
| Edginton, A.E., S. Willmann, W. Schmitt Predicting pharmacokinetics in children using PK-Sim® |
| H.E. Silber (1), P.M. Jauslin (1, 2), R. Gieschke (2), N. Frey (2), P. Vicini (3), U.S.H. Simonsson (1), M.O. Karlsson (1) A physiology based model for the glucose-insulin regulation in healthy volunteers and diabetic patients following intravenous glucose provocations. |
| M. Simeoni(1), P. H. Van Der Graaf(2), P. Milligan(2), D. Verotta(3), G. De Nicolao(1), M. Rocchetti(4), I. Poggesi(4) Counting events: population approaches using NONMEM |
| Nabil Semmar, Nicolas Simon Cluster analysis : an alternative method for covariate selection in population pharmacokinetics modeling |
| Liping Zhang (1, 2), Lewis B. Sheiner (3) Analyzing Multi-response Data Using Forcing Functions: illustrated in pharmacokinetic physiological flow modeling |
| Shafi Chowdhury (1), Alexander Staab (2), Karl-Heinz Liesenfeld (2), Carmen Burger (2), Modesta Wiersema (2) Producing NONMEM dataset using a standard SAS® program |
| CE Staatz (1,2), C Byrne (1), AH Thomson (1,2). Population pharmacokinetic modelling of gentamicin and vancomycin in patients with unstable renal function following cardiothoracic surgery |
| Donald R. Stanski, MD Model-Based Drug Development: A FDA Critical Path Opportunity |
| E. Pigeolet(1), P. Jacqmin(2), L. Sargentini-Maier(1) and A. Stockis(1) Retrospective Population Pharmacokinetic Analysis of Levetiracetam in Westerner and Japanese Adults |
| Armel Stockis (1) and Eric Snoeck (2) Dose-response analysis of levetiracetam add-on treatment in patients with partial epilepsy |
| A. Strougo(1), L. Zuurman(1), C. Roy(2), J.-L. Pinquier(2), A.F. Cohen(1), J.M.A. van Gerven(1), R. Schoemaker(1) PK and PK/PD Modelling of CNS Effects and Heart Rate After THC Administration in Humans |
| G. Fliss (1), A. Staab (2), C. Tillmann (2), D. Trommeshauser (2), H.G. Schaefer (2), C. Kloft (1) Development and evaluation of a population pharmacokinetic model for cilobradine, an If channel blocker |
| T.Tanigawa (1,2), T.Morikawa (2). H.To (2), S.Higuchi (2) A population PK model for nifedipine coat-core tablet |
| S. Tannenbaum (1,2), Nick Holford (2,4), H. Lee (2,3), C. Peck (2), D. Mould (5) A Novel Method for Simulation of Correlated Continuous and Categorical Variables Using A Single Multivariate Distribution |
| Diane Testart(1), Pascal GIRARD(1,4), Jean-Pierre Droz(2), Emilie Henin(1), Claude Ardiet(2), Sylvie Zanetta(3), Brigitte Tranchand(1,2) PK-PD model compared with K-PD model to predict haematotoxicity induced by anticancer drugs. |
| E. Tousset(1), B. Vrijens (1,2), J.-M. Métry (1), J. Urquhart (1,3) Non-Adherence to Prescribed Therapy is a Major Obstacle for Population PK/PD Studies |
| Pedro Berraondo1, Gloria González-Aseguinolaza1, Iñaki F. Trocóniz2 Application of Pharmacokinetic/Pharmacodynamic Concepts to Modeling in Gene Therapy |
| Iñaki F. Trocóniz 1, Christiane Tillmann 2, Dirk Trommeshauser2, Matthias Klueglich3, Juliet Roberts4, Hans G. Schaefer2 A New Model to Describe the Bradycardic Effects of If channel blockers in Healthy Volunteers |
| Tamara van Steeg(1), Elke Krekels(1), Jan Freijer(3), Fiona Macintyre(2) Meindert Danhof(1) and Elizabeth C.M. de Lange(1) The influence of an increase in plasma protein binding on the pharmacokinetics and pharmacodynamics of S(-)-Propranolol |
| A. Vermeulen, F. De Ridder Population PK/PD modeling of supine heart rate after oral administration of a new candidate antipsychotic drug |
| Oleg Volkov Patients’ Non-compliance with Drug Administration Times and Optimal Population Design in Pharmacokinetics. |
| Jeffrey Wald, Jagdev Sidhu, David Blum, and Marianne Silver Model Based Insights to Lamotrigine for Pain Associated with Diabetic Peripheral Neuropathy |
| Wenping Wang Positioning Drug Candidates in a Competitive Landscape - an integrated, data-driven approach |
| Justin J Wilkins (1, 2), G Langdon (1), H McIlleron (1), Goonaseelan Pillai (3), Peter J Smith (1), Ulrika S H Simonsson (2) Challenges in modelling the pharmacokinetics of isoniazid in South African tuberculosis patients |
| Justin J Wilkins (1), Fredrik Jonsson (1), Per-Henrik Zingmark (2), Patrick Lyden (3), E Niclas Jonsson (1) Predicting recovery progression in acute stroke using the Barthel Index |
| Demiana William Faltaos(1), Saïk Urien(1), Valérie Carreau(2), Marina Chauvenet(2), Jean Sebastian Hulot(1), Philippe Giral(2), Eric Bruckert(2), Philippe Lechat(1). Use of an indirect effect model to describe the LDL Cholesterol lowering process by statins |
| Miren K. Zamacona, Roberto Gomeni Modelling time varying kinetics using time dependent feedback control on clearance |
| Stefano Zamuner and Roberto Gomeni Use population approach to characterize PK time-course with erratic absorption |
| A.S. Zandvliet(1), S. Yasuda(2), W. Copalu(3), J.H.M. Schellens(4,5), J.H. Beijnen(1,5), A.D.R. Huitema(1) A physiologically based population pharmacokinetic model describing the non-linear disposition and blood distribution of indisulam in Caucasian and Japanese patients |
| PH Zingmark(1,2), M Kågedal (1), MO Karlsson(2) Modelling a spontaneously reported side-effect by use of a Markov mixed-effects model |
| A. Aldaz(1), L. Zufía(1), I. Aquerreta(1), A. Gúrpide(2), J. Giráldez(1). Pharmacokinetics of paclitaxel in liver transplantation cancer patients |
| L. Zufía(1), A. Aldaz(1), A. Ortega(1), F. Calvo(2), J. Giráldez(1) Tegafur and 5-Fluorouracil pelvic tissues concentrations in rectal cancer patients treated with preoperative chemoradiation. The processed sample stability investigation and their impact in the reability of data |
| Klaas P. Zuideveld (1) & Piet H. van der Graaf (2) Agonist-antagonist interaction models with slope factor: implications of an alternative derivation |
